Biomarkers are widely used not only as prognostic or diagnostic indicators, or as surrogate markers of disease in clinical trials, but also to formulate theories of pathogenesis. We identify two problems in the use of biomarkers in mechanistic studies. The first problem arises in the case of multifactorial diseases, where different combinations of multiple causes result in patient heterogeneity. The second problem arises when a pathogenic mediator is difficult to measure. This is the case of the oxidative stress (OS) theory of disease where the causal components are reactive oxygen species (ROS) that have very short half-lives. In this case, it is usual measure the traces left by the reaction of ROS with biological molecules, rather than the ROS themselves. Borrowing from the philosophical theories of signs, we look at the different facets of biomarkers and discuss their different value and meaning in multifactorial diseases and system medicine, to inform their use in patient stratification in personalized medicine.
INTRODUCTION
Molecular biomarkers can be defined as substances whose levels correlate with some pathological process. They are used as diagnostic or prognostic indicators, and to monitor the progression of disease in clinical trials (surrogate biomarkers) but also to formulate theories of disease. We recently discussed the problems related to the use of molecular biomarkers of OS (1, 2) in the context of the clinical translation of the OS theory of disease (3) . The present paper attempts to develop a theoretical framework for defining the different types of biomarkers using those of OS or inflammation as examples.
Inflammation and the cytokine theory of disease
Inflammation is largely mediated by activation of a gene expression profile, largely mapping to the transcription factor NF-kB, including inflammatory cytokines, adhesion molecules and enzymes involved in the synthesis of prostaglandins and nitric oxide. The most recent breakthrough in this field was the identification of inflammatory cytokines that led to the approval of specific inhibitors of IL-1, IL-6, IL-17 and TNF for the therapy of several inflammatory diseases, particularly rheumatoid arthritis (RA).
Following identification of TNF as an inflammatory mediator (4), the availability of specific assays for its measurement in biological fluids of patients with rheumatoid arthritis (RA) were instrumental in the translation of that hypothesis into the clinical arena (5) and the formulation of a "cytokine theory of disease" (6) . Just 14 years after the original finding, anti-TNF antibodies were a top selling biological drug.
The oxidative stress theory of disease and the use of indirect biomarkers
Oxidative stress is due to elevated levels of reactive oxygen species (ROS) (7) . Since the 1956 paper postulating a "free radical theory of aging" (8) , OS has been implicated as a causal factor in many disease (9) but, unlike the cytokine theory of disease, this has not led to any significant therapeutic breakthrough.
A major problem with the OS theory is that it is practically impossible to measure ROS in biological fluids because of their very short half-life, ranging from microseconds for superoxide and nanoseconds for hydroxyl radicals (10) . This difficulty applies of course to the measurement of ROS in patients and their biological fluids or biopsies, while generation of ROS by cell cultured in vitro can be measured more accurately. This is reminiscent of high-energy physics, where the short life of subatomic particles is such that these are detected only though the traces they leave during their decay. Likewise, OS biomarkers include oxidation products of biological molecules (11) . Unlike cytokines, we cannot measure ROS but we measure "signs" that stand for them instead, and in this paper, we try to look at biomarkers from the perspective of different philosophical theories of signs.
To do so, we will first recapitulate some key aspects of the main theories on signs that might be relevant to our problem, and attempt to draw links and similarities with biomarkers of inflammation and OS and their use in formulating theories of disease.
Concepts arising from various theories of signs
In the theory of signs of Charles Pierce (https://plato.stanford.edu/entries/peirce/), a sign is "something which stands to somebody for something in some respect or capacity" (12) . For Pierce, a sign is a component of a triad along with the interpretant and the object, or the "thing" the sign stands for. For instance, smoke is a sign for fire. If we (the interpretant) see smoke coming from behind a mountain, we assume that there is a wildfire somewhere (Fig.   1 ).
Pierce distinguishes different types of signs. While the smoke in Fig.1 is called an index, a street sign depicting a fire is also a sign that resembles, but is not physically related to, the object is an icon. A sign can stand for an event or an object, and one can distinguish different types of signs based on the relationship they have with the object.
The linguist Ferdinand de Saussure saw the language as a system of signs, where signs are related to other signs within the system, which led him to develop the concept that signs have a meaning (signification) but also a value. For instance, the knight, in the game of chess is a sign and has a meaning, the gentleman/soldier. However, it has also a value, but to appreciate that we need to see the knight in relation to the network of the other pieces in the game, its position on the chessboard and the rules of the game. Although the difference between value and meaning in de Saussure is not completely clear, we suggest that, for the use we will make of this concept, we consider value as something related to quantity (justified in this by the fact that de Saussure used also the example of the face value of a coin). We will develop later this concept that signs have a value that depends on the interactions among them.
Floridi recently analysed the differences between signs and proxies (13). Floridi's concept of proxy is different from that of Wittgenstein where "being proxy for" means "denoting", focusing instead on signs that exert an action, and on the direction of this action. Let's make the example of when, in Italian and French law, it's the major who can perform a wedding, but a city councillor can act on behalf of the mayor. This has been defined as a vicarious relation, where P is acting for R (the mayor). However, the direction of the action is one way, from R to P; a wedding conducted by a councillor is perfectly valid, but if we shoot the councillor the mayor will not die: if this was the case, then the councillor would be a proxy for the mayor.
This difference is outlined in Fig 2. What we want to retain here is that signs can be classified based on their functional relationship with the object, and that a proxy relationship goes both ways and you can interact on the proxy to affect the object it refers to.
In this analysis, Floridi distinguishes further between two types of signs with a vicarious relation. Those that are also signs that refer to R, in the sense they have a semiotic relationship with R, and signs that can act on behalf of/replace R but do not refer to it. The latter are defined surrogates (such as a PIN pad is a surrogate for a traditional key as it can perform the same function to open a door, but has no resemblance to a physical key).
Another concept that we would like to develop is that of the degrees of separations between the sign and the object they stand for, using again the example of smoke as a sign for fire. If there is a fire behind a mountain, the park ranger will see the smoke from an observation tower and call the fire department. Let's assume we are sitting in a café from a point from which we cannot see either the fire or the smoke. If we see several fire trucks with lights and sirens, we assume there is a fire, even if we can't see smoke. Now, let's say we are at home and we don't live by the main road. We don't see the fire, we don't see the smoke and we can't see the fire trucks but we hear several sirens going by; we can still assume that there is a fire somewhere.
We could say that, in this system, while smoke is directly related to fire (in the previous scheme) while the passage of the fire trucks is a sign that is one degree of separation from the object fire. Likewise, the sound of sirens will be two degrees of separation from the fire.
Fire --> smoke -(ranger on observation tower) --> fire trucks --> siren Importantly, the more are the degrees of separation from the object, the more the sign is ambiguous (less specific). The sign that is closest to the object, smoke, normally really means a fire. Four or five speeding fire trucks (one degree of separation) are a good indicator that there is a fire, but they may be there for an accident. Hearing several sirens (two degrees of separation) is not a very specific sign of a fire as they may be police cars or ambulances called for an accident. Thus, the degrees of separation between the object and the sign are important in the specificity of the signification.
The examples of diabetes, inflammation and oxidative stress
We will try to analyse two examples of molecular biomarkers used to define disease mechanisms, bearing in mind the points retained from the discussion above, particularly the concept of proxy and that of degrees of separation.
Let's start with a simple example. At the origin of diabetes there is a lack of production of, or response to, insulin. As a result, blood glucose increases leading to a number of pathological consequences. The blood level of glucose is a diagnostic biomarker for diabetes. In 1976 Cerami and colleagues discovered that exposure to high blood glucose resulted in the formation of glycated haemoglobin (HbA1c; Fig. 3 ) (14) . Both high levels of glucose and HbA1c are signs of diabetes. However, HbA1c is, for kinetics reasons, a better diagnostic biomarker (15) , even if it is more distant (two degrees of separation) from the mechanism of disease.
Let's look at the same scheme from the perspective of the identification of the mechanism of disease, or its therapy. High glucose has pathological consequences, and lowering its levels is good for the patient. However, drugs specifically targeting HbA1c would not modify the disease. While it may be a good surrogate biomarker in developing anti-diabetic drugs, HbA1c is not a proxy and acting on it will not act on the disease. In fact, some drugs, e.g. dapsone, reduce the levels of HbA1c, but this does not make diabetic patients better (16) .
A more complicated picture can be drawn for inflammatory diseases, such as rheumatoid arthritis (RA). To make our point, we have drawn an oversimplified scheme of the inflammatory network in RA, involving only few mediators (Fig. 4) . In this scheme, autoimmunity induces Th17 cells that, through the cytokine IL-17, activate macrophages to produce inflammatory cytokines (IL-1, IL-6 and TNF). The IL-1 produced by macrophages activated earlier is also a major inducer of IL-17. These will cause swelling or tissue damage, either directly or via prostaglandins such as PGE2. IL-6 also acts on the liver to induce acutephase proteins such as C-reactive protein (CRP) and fibrinogen, and decreasing the synthesis of albumin. IL-17 is directly related to autoimmunity, one degree of separation, while IL-1 and TNF are two degrees of separation away, IL-6 both two and three, PGE2 and CRP four. Although the cytokines listed (IL-1, IL-6, IL-17, TNF) are elevated in RA patients (17) , only CRP is an established biomarker of disease (18) and is used for both diagnosis and as a surrogate marker in clinical trials.
In terms of disease mechanism, however, IL-17, IL-1, IL-6 and TNF are proxies. Acting on them we act on the disease, and antibodies that neutralize these cytokines are approved therapies for RA. On the other hand, CRP is normally viewed as a protective molecule and its absence, in animal models, is not protective against arthritis (19, 20) ; therefore, CRP can be considered a sign, possibly a surrogate, but not a proxy.
Let us now consider OS. According to its definition (7), OS occurs when the concentrations of reactive oxygen species (ROS) increase. One of the most reactive ROS is the hydroxyl radical (OH.) that reacts with lipids, to initiate a chain reaction called lipid peroxidation, and nucleic acids. Its short half-life forces us to use biomarkers that are the result of its interaction with those biological molecules, and we will consider two of them. Another question is whether OS biomarkers can be proxies. The main problem with the OS theory of disease is the difficulty of measuring the causative agents, ROS, unlike the cytokine theory of disease or the germ theory of disease where cytokines and microbes can be measured in biological fluids. This means that none of the biomarkers of OS used in most of the studies are proxies.
Mathematical and statistical method for the validation of mechanistic biomarkers and the problem of multicausality
When novel biomarkers are proposed, they are usually measured in a cohort of patients compared with healthy people or patients with unrelated disease. Then, a statistical comparison of the levels among two or more groups is done using the classical frequentist statistics, that calculates the probability that there is no difference between the two groups (the theoretical null hypothesis) (22) . Another approach is to assess the probability that the biomarker levels correlate with the severity of a disease, a clinical score, or an outcome. The limitations of approaches based on the null hypothesis significance testing, with its dichotomization of evidence, have been discussed recently (23) . The size of the patient population investigated is also decided on the basis of conventional "power analysis", usually designed to meet the goals of the classical significance testing (24) .
The problem of validating biomarkers that we can use to build theories of disease, be they proxies (such as TNF or IL-6) or just signs (such as CRP or 8-OH-G), is that while the usual statistical approach may be useful for surrogate biomarkers, we can apply it to mechanism biomarkers only for disease that have a single cause, while many diseases are multifactorial, a result of multiple causes. This is typically represented by the so-called Rothman's causal pies (25) . We could assume, for instance, that RA develops when a number of component causes add up to form a sufficient cause (the pie). However, the same disease could develop by a different combination of component causes to make a different sufficient cause.
Oxidative stress has been implicated as a causal component in many diseases, including RA (9) . Clearly, it must be a component cause because not all people with evidence of high OS develop RA. The question then arises, if OS is a slice in the causal pie for RA, is it a necessary component cause? That would mean that OS is always needed, for the disease to develop and, therefore, all patients with RA will have OS (in red, Fig.6A ). However, it is also possible that OS is a component cause only in one of the many possible sufficient causes, an in this case OS will be present in some patients but not in others. In this case, not all the patients with RA will have OS but only those with one specific sufficient cause (Fig.6B) . These two possibilities are represented along with the third possibility (Fig.6C) , whereby OS is, alone, a sufficient cause of RA, and is present in all patients.
If we measure biomarkers of OS in these patients, the classical statistical approach using the null hypothesis significance testing would only give a positive result in the case of mechanisms A and C. In the case depicted in panel B, if OS was implicated only in some patients, we would not find a significant difference in the level of biomarker in a cohort of patients compared to healthy controls, or a correlation with disease severity/outcome.
Classical statistics has ways to analyze subpopulations of patients by stratification for covariates (e.g. gender, ethnicity, age etc.), but this would not help.
What is needed here is to first validate that higher levels of a biomarker signify that OS is present in a specific patient, and then use that biomarker to identify those RA patients that have OS. It is difficult to name a clinically-validated biomarker of OS because there are not clinical conditions where OS is present in all patients (although radiation toxicity and ozone toxicity would get close (26)). Considering the additional problem of lack of specificity, it would be appropriate to use a different approach. We need to confirm that, in each patient, higher ROS levels are produced by measuring several OS biomarkers: we need to disambiguate the meaning of a sign. Exactly as it happens when we disambiguate the meaning of words, we need to look at the context. If we read a paper where MDA is measured in a study on diet and OS, we know its meaning is as a biomarker of OS, while if the context is that of a drug acting on platelet activation, we can extrapolate that MDA is intended as a biomarker of arachidonate metabolism.
In patients, to find the value of a biomarker, and to validate it as an indicator of OS, one approach to disambiguate its meaning could be to look at another OS biomarker -another sign in the same system. Thus, in biomarkers, we need to see them in the context of other biomarkers in the same system also to disambiguate their meaning, not just to appreciate their value.
Along the line of "systems of signs" another possibility is that, before any statistical analysis, we visualize the data in a network, both to identify potential patient subpopulations and to disambiguate the meaning of the biomarkers measured.
We performed a proof-of-principle analysis of the levels of various OS biomarkers in different diseases (2) . The data, obtained from published literature, consisted in a spreadsheet with different diseases and, for each of them, the OS biomarker that was reported elevated in that disease. These data were analysed using hierarchical cluster analysis to visualize the similarities between different diseases in terms of pattern of OS biomarkers (2).
A second type of visualization is based on a network analysis, originally used to identify the "diseasome", by which different diseases are connected based on genetic risk factors, subsequently extended to protein-protein interactions (27) (28) (29) .
Using published data (2), we have created a disease network based on the common OS biomarkers, as described in the Methods section. The result is shown in Fig.7 , depicting the vicinity of diseases based on commonly elevated biomarkers.
This type of analysis, applied to biomarkers related to different disease mechanisms (inflammation, OS, autoimmunity, viral antibodies etc.), could be used to identify diseases with common pathogenic mechanisms. It could also be applied to patients with a single disease to identify patients with different causal components in order to assign each patient to a hypothetical Rothman's causal pie. This approach might then be followed by correlation analysis and classical significance testing to assess whether differences in the levels of biomarkers among different subgroups are robust. Along this line, a Bayesian latent hierarchical model has been proposed to identify meta-patterns of biomarkers in different cohort to facilitate hypothesis generation (30) .
Constraints in biomarker discovery
Several conventions limit the study of biomarkers that identify causal components of disease. Statistical analysis based on the null hypothesis significance testing is a prerequisite for publication, in what has been defined a "lexicographic decision rule" (23) . Funding agencies and ethical committees require a standard "research methodology" involving the use of power analysis to identify patients group size, tailored to satisfy classical significance testing. For this reason, most of the studies on the "diseasome" published so far have been done analyzing published literature or databases rather than with laboratory or clinical studies.
Another constraint is the drive to develop diagnostic/prognostic biomarkers to meet real clinical needs (such as diagnosis of cancer) or drug development needs, where surrogate biomarkers are used for the approval on new drugs instead of clinical outcomes (31) . These constraints favour the discovery and validation of biomarkers that often do not provide indication on the mechanism of disease.
Let's go back once more to the OS theory of disease and the various possibilities outlined in Fig. 6 . It is possible that OS is a causal component in RA, but it is also possible that it is a consequence of the disease, for instance secondary to inflammation or joint damage. If OS is a causal component and the disease has multiple causes as in Fig. 6B , we will not be able to find a statistically significant difference between a healthy group and a disease one.
However, if OS was not a cause, but a result of the disease, i.e. a "biochemical symptom" or a causally-irrelevant by-product, then it would be present in all patients and, possibly, correlate with disease severity. Paradoxically, in multicausal disease, the more distant from the mechanism of disease is the biomarker, the more likely it is that it will be validated (and published) using classical significance testing. For instance, in Fig. 4 , CRP is a better biomarker than IL-17 or TNF. Conventional statistical analysis and study design will favour the identification of causally-irrelevant prognostic biomarker even when the study was aimed at investigating the mechanism of disease.
Artificial intelligence, big data and the problem of the interpretant.
For Pierce, the interpretant in Fig. 1 is a human mind and all the discussion in this paper implied a researcher/practitioner interpreting the meaning. If a biomarker is the carrier of a message, in medical semiotic "an observation that does not convey a message is not a sign" (32) . However, -omics and big data may generate messages not intelligible to a human. An example is the use of gene expression profiling to identify arthritis patients that would benefit from biologicals. These studies analyzed the expression of tens of thousands of genes in drugs-responsive and non-responsive patients and identified algorithms, derived from the expression of up to 200 genes and cluster analysis, that correlate with drug responsiveness (33, 34) . Only few of these genes will have a place in the theories about the mechanism of disease, because the function of many of them is not known, and the cluster will have no meaning for the human interpretant. This will require an entirely different approach and raises the challenging question on whether the theories of signs and the concept of "meaning", and their application to biomarkers, need to be modified when interpreting big data. This is similar to the example cited by Evans on GPS navigation: "the physical world is translated into a database of instructions and distances, and interpreted by the application into a route to follow. . . The application then presents the world back to the user in a mediated form . . . which is used, to navigate the route " (35) . Clearly an algorithm, or cluster of genes and transcripts, can represent a surrogate sign, as it can act on behalf of/replace the disease (and be used, for instance, as secondary outcomes in a clinical trial) without referring to it.
While the focus on biomarkers generated by high-throughput techniques has been on their diagnostic and prognostic use, their use in building mechanistic theories of disease will require a different theoretical and statistical approach. This is important in mechanismbased patient stratification and in the translation of the concept of personalized medicine.
METHODS
The data were processed in GNU R and visualised as a graph. Thereafter, the graph was saved in a format that can be loaded into Gephi for exploratory analysis. The source data are represented as a matrix where each row in the matrix represents whether each of the 20 biomarkers indicate the presence of a disease. In general, either a biomarker is elevated in a disease, according to the small sample of the literature analysed, or it does not. The binary nature of these observations lend themselves to computing the similarity of diseases using a Jaccard index (36) . The Jaccard distance between diseases is normalised between 0 and 1. The more similarity between diseases the closer their Jaccard distance is to 0. The computed matrix of Jaccard distances is then transformed into a matrix of edge weights and presented using a force-directed graph layout algorithm (37) . In our graph layout, the 
